# A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

> **NCT02607124** · PHASE1,PHASE2 · TERMINATED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 11 (actual)

## Conditions studied

- High Grade Glioma
- Diffuse Intrinsic Pontine Glioma
- Bithalamic High Grade Glioma

## Interventions

- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT02607124
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2018-05
- **Final completion:** 2018-08
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** A competing trial was opened for patient population with combination of ribociclib and everolimus.
- **Last updated:** 2020-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607124, "A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02607124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*